Apellis Pharmaceuticals Inc. (APLS) saw its stock price plummet 5.23% in pre-market trading on Wednesday, following the release of its first-quarter 2025 financial results. The biopharmaceutical company's report revealed ongoing challenges in achieving profitability despite growing product revenue.

According to the quarterly report, Apellis posted a basic earnings per share (EPS) of USD -0.74, indicating a significant loss. The company's net income for Q1 2025 stood at USD -92.225 million, while operating income was reported at USD -83.328 million. These figures highlight the company's continued struggle to turn a profit, despite generating product revenue of USD 149.9 million for the quarter.

Investors appear to be concerned about Apellis' high operating expenses, which reached USD 250.125 million in Q1. This substantial spending, significantly outpacing the company's revenue, suggests that Apellis is still in a phase of heavy investment in research and development or market expansion. While such investments may be necessary for long-term growth, the immediate impact on the company's financial health seems to have spooked investors, leading to the pre-market sell-off.